Drug resistance analysis by next generation sequencing in Leishmania

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 5, Issue 1, 2015, Pages 26-35

  Leprohon, Philippe ^a,b   Fernandez Prada, Christopher ^a,b   Gazanion, Élodie ^a,b   Monte Neto, Rubens ^a,b   Ouellette, Marc ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aneuploidy; Drug resistance; Gene amplification; Genome; Leishmania; Next generation sequencing; Single nucleotide polymorphisms

Indexed keywords

AMINOGLYCOSIDE PAROMOMYCIN; AMPHOTERICIN B LIPID COMPLEX; ANTIPARASITIC AGENT; PAROMOMYCIN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT;

CHROMOSOME NUMBER; CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; DNA STRAND; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE DUPLICATION; GENE EXPRESSION; GENE INACTIVATION; GENE REARRANGEMENT; GENETIC VARIABILITY; GENOME ANALYSIS; HOMOLOGOUS RECOMBINATION; HUMAN; LEISHMANIA; LEISHMANIASIS; MUCO CUTANEOUS LEISHMANIASIS; NEXT GENERATION SEQUENCING; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN LEISHMANIASIS; TRANSCRIPTION INITIATION; VISCERAL LEISHMANIASIS; DRUG EFFECTS; DRUG RESISTANCE; GENETIC VARIATION; GENETICS; NUCLEIC ACID AMPLIFICATION; PROCEDURES;

ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; GENETIC VARIATION; LEISHMANIA; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 84924577640     PISSN: None     EISSN: 22113207     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2014.09.005     Document Type: Review

References (139)

1. Akopyants N.S., Kimblin N., Secundino N., Patrick R., Peters N., Lawyer P., Dobson D.E., Beverley S.M., Sacks D.L. Demonstration of genetic exchange during cyclical development of Leishmania in the sand fly vector. Science 2009, 324:265-268.
2. Ali J.A., Creek D.J., Burgess K., Allison H.C., Field M.C., Maser P., De Koning H.P. Pyrimidine salvage in Trypanosoma brucei bloodstream forms and the trypanocidal action of halogenated pyrimidines. Mol. Pharmacol. 2013, 83:439-453.
3. Alvar J., Velez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PloS One 2012, 7:e35671.
4. Arrebola R., Olmo A., Reche P., Garvey E.P., Santi D.V., Ruiz-Perez L.M., Gonzalez-Pacanowska D. Isolation and characterization of a mutant dihydrofolate reductase-thymidylate synthase from methotrexate-resistant Leishmania cells. J. Biol. Chem. 1994, 269:10590-10596.
5. Ashutosh, Garg M., Sundar S., Duncan R., Nakhasi H.L., Goyal N. Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob. Agents Chemother. 2012, 56:518-525.
6. Bahassi E.M., Stambrook P.J. Next-generation sequencing technologies: breaking the sound barrier of human genetics. Mutagenesis 2014, 29:303-310.
7. Berman J.D., Badaro R., Thakur C.P., Wasunna K.M., Behbehani K., Davidson R., Kuzoe F., Pang L., Weerasuriya K., Bryceson A.D. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 1998, 76:25-32.
8. Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R.N., Figueras C., Gradoni L., Kafetzis D.A., Ritmeijer K., Rosenthal E., Royce C., Russo R., Sundar S., Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 2006, 43:917-924.
9. Beverley S.M. Gene amplification in Leishmania. Annu. Rev. Microbiol. 1991, 45:417-444.
10. Beverley S.M., Coburn C.M. Recurrent de novo appearance of small linear DNAs in Leishmania major and relationship to extra-chromosomal DNAs in other species. Mol. Biochem. Parasitol. 1990, 42:133-141.
11. Beverley S.M., Coderre J.A., Santi D.V., Schimke R.T. Unstable DNA amplifications in methotrexate-resistant Leishmania consist of extrachromosomal circles which relocalize during stabilization. Cell 1984, 38:431-439.
12. Boisvert S., Laviolette F., Corbeil J. Ray: simultaneous assembly of reads from a mix of high-throughput sequencing technologies. J. Comput. Biol.: J. Comput. Mol. Cell Biol. 2010, 17:1519-1533.
13. Britto C., Ravel C., Bastien P., Blaineau C., Pages M., Dedet J.P., Wincker P. Conserved linkage groups associated with large-scale chromosomal rearrangements between Old World and New World Leishmania genomes. Gene 1998, 222:107-117.
14. Brotherton M.C., Bourassa S., Leprohon P., Legare D., Poirier G.G., Droit A., Ouellette M. Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant. PloS ONE 2013, 8. e81899.
15. Buermans H.P., den Dunnen J.T. Next generation sequencing technology: advances and applications. Biochimica et biophysica acta 2014.
16. Castanys-Munoz E., Perez-Victoria J.M., Gamarro F., Castanys S. Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob. Agents Chemother. 2008, 52:3573-3579.
17. Chen G., Bradford W.D., Seidel C.W., Li R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature 2012, 482:246-250.
18. Coderre J.A., Beverley S.M., Schimke R.T., Santi D.V. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:2132-2136.
19. Coelho A.C., Boisvert S., Mukherjee A., Leprohon P., Corbeil J., Ouellette M. Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl. Trop. Dis. 2012, 6:e1512.
20. Croft S.L., Neal R.A., Pendergast W., Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 1987, 36:2633-2636.
21. Cruz A.K., Titus R., Beverley S.M. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1599-1603.
22. DePristo M.A., Banks E., Poplin R., Garimella K.V., Maguire J.R., Hartl C., Philippakis A.A., del Angel G., Rivas M.A., Hanna M., McKenna A., Fennell T.J., Kernytsky A.M., Sivachenko A.Y., Cibulskis K., Gabriel S.B., Altshuler D., Daly M.J. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011, 43:491-498.
23. do Monte-Neto R.L., Coelho A.C., Raymond F., Legare D., Corbeil J., Melo M.N., Frezard F., Ouellette M. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl. Trop. Dis. 2011, 5:e1167.
24. Downing T., Imamura H., Decuypere S., Clark T.G., Coombs G.H., Cotton J.A., Hilley J.D., de Doncker S., Maes I., Mottram J.C., Quail M.A., Rijal S., Sanders M., Schonian G., Stark O., Sundar S., Vanaerschot M., Hertz-Fowler C., Dujardin J.C., Berriman M. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011, 21:2143-2156.
25. Downing T., Stark O., Vanaerschot M., Imamura H., Sanders M., Decuypere S., de Doncker S., Maes I., Rijal S., Sundar S., Dujardin J.C., Berriman M., Schonian G. Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect. Genet. Evol.: J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2012, 12:149-159.
26. Dubessay P., Ravel C., Bastien P., Lignon M.F., Ullman B., Pages M., Blaineau C. Effect of large targeted deletions on the mitotic stability of an extra chromosome mediating drug resistance in Leishmania. Nucl. Acids Res. 2001, 29:3231-3240.
27. Dumas C., Ouellette M., Tovar J., Cunningham M.L., Fairlamb A.H., Tamar S., Olivier M., Papadopoulou B. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. Embo. J. 1997, 16:2590-2598.
28. El-Halfawy O.M., Valvano M.A. Chemical communication of antibiotic resistance by a highly resistant subpopulation of bacterial cells. PloS One 2013, 8:e68874.
29. Fonseca N.A., Rung J., Brazma A., Marioni J.C. Tools for mapping high-throughput sequencing data. Bioinformatics 2012, 28:3169-3177. (Oxford, England).
30. Garcia-Hernandez R., Manzano J.I., Castanys S., Gamarro F. Leishmania donovani develops resistance to drug combinations. PLoS Negl. Trop. Dis. 2012, 6:e1974.
31. Garvey E.P., Santi D.V. Stable amplified DNA in drug-resistant Leishmania exists as extrachromosomal circles. Science 1986, 233:535-540.
32. Gnerre S., Maccallum I., Przybylski D., Ribeiro F.J., Burton J.N., Walker B.J., Sharpe T., Hall G., Shea T.P., Sykes S., Berlin A.M., Aird D., Costello M., Daza R., Williams L., Nicol R., Gnirke A., Nusbaum C., Lander E.S., Jaffe D.B. High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1513-1518.
33. Gonzalez, U., Pinart, M., Rengifo-Pardo, M., Macaya, A., Alvar, J., Tweed, J.A., 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. The Cochrane database of systematic reviews, CD004834.
34. Gourbal B., Sonuc N., Bhattacharjee H., Legare D., Sundar S., Ouellette M., Rosen B.P., Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 2004, 279:31010-31017.
35. Grondin K., Papadopoulou B., Ouellette M. Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant Leishmania. Nucl. Acids Res. 1993, 21:1895-1901.
36. Grondin K., Kundig C., Roy G., Ouellette M. Linear amplicons as precursors of amplified circles in methotrexate-resistant Leishmania tarentolae. Nucl. Acids Res. 1998, 26:3372-3378.
37. Guimond C., Trudel N., Brochu C., Marquis N., El Fadili A., Peytavi R., Briand G., Richard D., Messier N., Papadopoulou B., Corbeil J., Bergeron M.G., Legare D., Ouellette M. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucl. Acids Res. 2003, 31:5886-5896.
38. Haile S., Papadopoulou B. Developmental regulation of gene expression in trypanosomatid parasitic protozoa. Curr. Opin. Microbiol. 2007, 10:569-577.
39. Hailu A., Musa A., Wasunna M., Balasegaram M., Yifru S., Mengistu G., Hurissa Z., Hailu W., Weldegebreal T., Tesfaye S., Makonnen E., Khalil E., Ahmed O., Fadlalla A., El-Hassan A., Raheem M., Mueller M., Koummuki Y., Rashid J., Mbui J., Mucee G., Njoroge S., Manduku V., Musibi A., Mutuma G., Kirui F., Lodenyo H., Mutea D., Kirigi G., Edwards T., Smith P., Muthami L., Royce C., Ellis S., Alobo M., Omollo R., Kesusu J., Owiti R., Kinuthia J. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl. Trop. Dis. 2010, 4:e709.
40. Haimeur A., Ouellette M. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrob. Agents Chemother. 1998, 42:1689-1694.
41. Hammond D.J., Gutteridge W.E. UMP synthesis in the kinetoplastida. Biochim. Biophys. Acta 1982, 718:1-10.
42. Henry, V.J., Bandrowski, A.E., Pepin, A.S., Gonzalez, B.J., Desfeux, A., 2014. OMIC tools: an informative directory for multi-omic data analysis. Database: J. Biol. Databases Curation 2014.
43. Ivens A.C., Peacock C.S., Worthey E.A., Murphy L., Aggarwal G., Berriman M., Sisk E., Rajandream M.A., Adlem E., Aert R., Anupama A., Apostolou Z., Attipoe P., Bason N., Bauser C., Beck A., Beverley S.M., Bianchettin G., Borzym K., Bothe G., Bruschi C.V., Collins M., Cadag E., Ciarloni L., Clayton C., Coulson R.M., Cronin A., Cruz A.K., Davies R.M., De Gaudenzi J., Dobson D.E., Duesterhoeft A., Fazelina G., Fosker N., Frasch A.C., Fraser A., Fuchs M., Gabel C., Goble A., Goffeau A., Harris D., Hertz-Fowler C., Hilbert H., Horn D., Huang Y., Klages S., Knights A., Kube M., Larke N., Litvin L., Lord A., Louie T., Marra M., Masuy D., Matthews K., Michaeli S., Mottram J.C., Muller-Auer S., Munden H., Nelson S., Norbertczak H., Oliver K., O'Neil S., Pentony M., Pohl T.M., Price C., Purnelle B., Quail M.A., Rabbinowitsch E., Reinhardt R., Rieger M., Rinta J., Robben J., Robertson L., Ruiz J.C., Rutter S., Saunders D., Schafer M., Schein J., Schwartz D.C., Seeger K., Seyler A., Sharp S., Shin H., Sivam D., Squares R., Squares S., Tosato V., Vogt C., Volckaert G., Wambutt R., Warren T., Wedler H., Woodward J., Zhou S., Zimmermann W., Smith D.F., Blackwell J.M., Stuart K.D., Barrell B., Myler P.J. The genome of the kinetoplastid parasite, Leishmania major. Science 2005, 309:436-442.
44. Jha T.K., Olliaro P., Thakur C.P., Kanyok T.P., Singhania B.L., Singh I.J., Singh N.K., Akhoury S., Jha S. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Bmj 1998, 316:1200-1205.
45. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 1999, 341:1795-1800.
46. Katakura K., Fujise H., Takeda K., Kaneko O., Torii M., Suzuki M., Chang K.P., Hashiguchi Y. Overexpression of LaMDR2, a novel multidrug resistance ATP-binding cassette transporter, causes 5-fluorouracil resistance in Leishmania amazonensis. FEBS Lett. 2004, 561:207-212.
47. Koren S., Schatz M.C., Walenz B.P., Martin J., Howard J.T., Ganapathy G., Wang Z., Rasko D.A., McCombie W.R., Jarvis E.D., Adam M.P. Hybrid error correction and de novo assembly of single-molecule sequencing reads. Nat. Biotechnol. 2012, 30:693-700.
48. Kumar P., Lodge R., Raymond F., Ritt J.F., Jalaguier P., Corbeil J., Ouellette M., Tremblay M.J. Gene expression modulation and the molecular mechanisms involved in Nelfinavir resistance in Leishmania donovani axenic amastigotes. Mol. Microbiol. 2013, 89:565-582.
49. Lachaud L., Bourgeois N., Kuk N., Morelle C., Crobu L., Merlin G., Bastien P., Pages M., Sterkers Y. Constitutive mosaic aneuploidy is a unique genetic feature widespread in the Leishmania genus. Microbes Infect./Institut Pasteur 2014, 16:61-66.
50. Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 2012, 9:357-359.
51. Laurent T., Rijal S., Yardley V., Croft S., De Doncker S., Decuypere S., Khanal B., Singh R., Schonian G., Kuhls K., Chappuis F., Dujardin J.C. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infect. Genet. Evol.: J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2007, 7:206-212.
52. Lee H.H., Molla M.N., Cantor C.R., Collins J.J. Bacterial charity work leads to population-wide resistance. Nature 2010, 467:82-85.
53. Leprohon P., Legare D., Ouellette M. Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials. Antimicrob. Agents Chemother. 2009, 53:2646-2649.
54. Leprohon P., Legare D., Raymond F., Madore E., Hardiman G., Corbeil J., Ouellette M. Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucl. Acids Res. 2009, 37:1387-1399.
55. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760. (Oxford, England).
56. Li H., Ruan J., Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 2008, 18:1851-1858.
57. Li R., Li Y., Kristiansen K., Wang J. SOAP: short oligonucleotide alignment program. Bioinformatics 2008, 24:713-714. (Oxford, England).
58. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999, 180:564-567.
59. Liu L., Li Y., Li S., Hu N., He Y., Pong R., Lin D., Lu L., Law M. Comparison of next-generation sequencing systems. J. Biomed. Biotechnol. 2012, 2012:251364.
60. Luo R., Liu B., Xie Y., Li Z., Huang W., Yuan J., He G., Chen Y., Pan Q., Liu Y., Tang J., Wu G., Zhang H., Shi Y., Yu C., Wang B., Lu Y., Han C., Cheung D.W., Yiu S.M., Peng S., Xiaoqian Z., Liu G., Liao X., Li Y., Yang H., Wang J., Lam T.W. SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. GigaScience 2012, 1:18.
61. Lye L.F., Owens K., Shi H., Murta S.M., Vieira A.C., Turco S.J., Tschudi C., Ullu E., Beverley S.M. Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog. 2010, 6:e1001161.
62. Maretti-Mira A.C., Bittner J., Oliveira-Neto M.P., Liu M., Kang D., Li H., Pirmez C., Craft N. Transcriptome patterns from primary cutaneous Leishmania braziliensis infections associate with eventual development of mucosal disease in humans. PLoS Negl. Trop. Dis. 2012, 6:e1816.
63. Marquis N., Gourbal B., Rosen B.P., Mukhopadhyay R., Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol. Microbiol. 2005, 57:1690-1699.
64. Martin J.L., Yates P.A., Soysa R., Alfaro J.F., Yang F., Burnum-Johnson K.E., Petyuk V.A., Weitz K.K., Camp D.G., Smith R.D., Wilmarth P.A., David L.L., Ramasamy G., Myler P.J., Carter N.S. Metabolic reprogramming during purine stress in the protozoan pathogen Leishmania donovani. PLoS Pathog. 2014, 10:e1003938.
65. Martinez-Calvillo S., Yan S., Nguyen D., Fox M., Stuart K., Myler P.J. Transcription of Leishmania major Friedlin chromosome 1 initiates in both directions within a single region. Mol. Cell. 2003, 11:1291-1299.
66. Martinez-Calvillo S., Nguyen D., Stuart K., Myler P.J. Transcription initiation and termination on Leishmania major chromosome 3. Eukaryot. Cell 2004, 3:506-517.
67. Martinez-Calvillo S., Stuart K., Myler P.J. Ploidy changes associated with disruption of two adjacent genes on Leishmania major chromosome 1. Int. J. Parasitol. 2005, 35:419-429.
68. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010, 20:1297-1303.
69. Meheus F., Balasegaram M., Olliaro P., Sundar S., Rijal S., Faiz M.A., Boelaert M. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl. Trop. Dis. 2010, 4.
70. 2+, and glutathione. Free Radic. Biol. Med. 2006, 40:1857-1868.
71. Mittra B., Cortez M., Haydock A., Ramasamy G., Myler P.J., Andrews N.W. Iron uptake controls the generation of Leishmania infective forms through regulation of ROS levels. J. Exp. Med. 2013, 210:401-416.
72. Mohamed-Ahmed A.H., Brocchini S., Croft S.L. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Curr. Opin. Infect. Dis. 2012, 25:695-702.
73. Monte-Neto, R., Laffitte, M.C., Leprohon, P., Reis, P., Frézard, F., Ouellette, M., Intrachromosomal Amplification, Locus Deletion and Point Mutation in the Aquaglyceroporin AQP1 Gene in Antimony Resistant Leishmania (Viannia) guyanensis, submitted.
74. Moreira W., Leprohon P., Ouellette M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis. 2011, 2:e201.
75. Mottram J.C., McCready B.P., Brown K.G., Grant K.M. Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmania mexicana. Mol. Microbiol. 1996, 22:573-583.
76. Mukherjee A., Langston L.D., Ouellette M. Intrachromosomal tandem duplication and repeat expansion during attempts to inactivate the subtelomeric essential gene GSH1 in Leishmania. Nucl. Acids Res. 2011, 39:7499-7511.
77. Mukherjee A., Boisvert S., Monte-Neto R.L., Coelho A.C., Raymond F., Mukhopadhyay R., Corbeil J., Ouellette M. Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania. Mol. Microbiol. 2013, 88:189-202.
78. Muller M., Padmanabhan P.K., Papadopoulou B. Selective inactivation of SIDER2 retroposon-mediated mRNA decay contributes to stage- and species-specific gene expression in Leishmania. Mol. Microbiol. 2010, 77:471-491.
79. Muller M., Padmanabhan P.K., Rochette A., Mukherjee D., Smith M., Dumas C., Papadopoulou B. Rapid decay of unstable Leishmania mRNAs bearing a conserved retroposon signature 3'-UTR motif is initiated by a site-specific endonucleolytic cleavage without prior deadenylation. Nucl. Acids Res. 2010, 38:5867-5883.
80. Musa A.M., Younis B., Fadlalla A., Royce C., Balasegaram M., Wasunna M., Hailu A., Edwards T., Omollo R., Mudawi M., Kokwaro G., El-Hassan A., Khalil E. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl. Trop. Dis. 2010, 4:e855.
81. Navarro M., Liu J., Muthui D., Ortiz G., Segovia M., Hamers R. Inverted repeat structure and homologous sequences in the LD1 amplicons of Leishmania spp. Mol. Biochem. Parasitol. 1994, 68:69-80.
82. Ning Z., Cox A.J., Mullikin J.C. SSAHA: a fast search method for large DNA databases. Genome Res. 2001, 11:1725-1729.
83. Nowrousian M. Next-generation sequencing techniques for eukaryotic microorganisms: sequencing-based solutions to biological problems. Eukaryot. Cell 2010, 9:1300-1310.
84. Olliaro P.L. Drug combinations for visceral leishmaniasis. Curr. Opin. Infect. Dis. 2010, 23:595-602.
85. Olmo A., Arrebola R., Bernier V., Gonzalez-Pacanowska D., Ruiz-Perez L.M. Co-existence of circular and multiple linear amplicons in methotrexate-resistant Leishmania. Nucl. Acids Res. 1995, 23:2856-2864.
86. Ouameur A.A., Girard I., Legare D., Ouellette M. Functional analysis and complex gene rearrangements of the folate/biopterin transporter (FBT) gene family in the protozoan parasite Leishmania. Mol. Biochem. Parasitol. 2008, 162:155-164.
87. Ouellette M., Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitol. Today 1993, 9:150-153.
88. Ouellette M., Hettema E., Wust D., Fase-Fowler F., Borst P. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. Embo. J 1991, 10:1009-1016.
89. Ouellette M., Haimeur A., Grondin K., Legare D., Papadopoulou B. Amplification of ABC transporter gene pgpA and of other heavy metal resistance genes in Leishmania tarentolae and their study by gene transfection and gene disruption. Methods Enzymol. 1998, 292:182-193.
90. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-1724.
91. Papadopoulou B., Roy G., Ouellette M. Frequent amplification of a short chain dehydrogenase gene as part of circular and linear amplicons in methotrexate resistant Leishmania. Nucl. Acids Res. 1993, 21:4305-4312.
92. Pathak M.K., Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 2001, 167:3391-3397.
93. Peacock C.S., Seeger K., Harris D., Murphy L., Ruiz J.C., Quail M.A., Peters N., Adlem E., Tivey A., Aslett M., Kerhornou A., Ivens A., Fraser A., Rajandream M.A., Carver T., Norbertczak H., Chillingworth T., Hance Z., Jagels K., Moule S., Ormond D., Rutter S., Squares R., Whitehead S., Rabbinowitsch E., Arrowsmith C., White B., Thurston S., Bringaud F., Baldauf S.L., Faulconbridge A., Jeffares D., Depledge D.P., Oyola S.O., Hilley J.D., Brito L.O., Tosi L.R., Barrell B., Cruz A.K., Mottram J.C., Smith D.F., Berriman M. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007, 39:839-847.
94. Perez-Victoria F.J., Gamarro F., Ouellette M., Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003, 278:49965-49971.
95. Perez-Victoria F.J., Sanchez-Canete M.P., Castanys S., Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem. 2006, 281:23766-23775.
96. Petrillo-Peixoto M.L., Beverley S.M. Amplified DNAs in laboratory stocks of Leishmania tarentolae: extrachromosomal circles structurally and functionally similar to the inverted-H-region amplification of methotrexate-resistant Leishmania major. Mol. Cell. Biol. 1988, 8:5188-5199.
97. Rando O.J. Chromatin structure in the genomics era. Trends Genet.: TIG 2007, 23:67-73.
98. Rastrojo A., Carrasco-Ramiro F., Martin D., Crespillo A., Reguera R.M., Aguado B., Requena J.M. The transcriptome of Leishmania major in the axenic promastigote stage: transcript annotation and relative expression levels by RNA-seq. BMC Genomics 2013, 14:223.
99. Raymond F., Boisvert S., Roy G., Ritt J.F., Legare D., Isnard A., Stanke M., Olivier M., Tremblay M.J., Papadopoulou B., Ouellette M., Corbeil J. Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucl. Acids Res. 2012, 40:1131-1147.
100. Real, F., Vidal, R.O., Carazzolle, M.F., Mondego, J.M., Costa, G.G., Herai, R.H., Wurtele, M., de Carvalho, L.M., RC, E.F., Mortara, R.A., Barbieri, C.L., Mieczkowski, P., da Silveira, J.F., Briones, M.R., Pereira, G.A., Bahia, D., 2013. The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models. DNA Res.: Int. J. Rapid Publ. Reports Genes Genomes.
101. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis. 2007, 7:581-596.
102. Rijal S., Chappuis F., Singh R., Bovier P.A., Acharya P., Karki B.M., Das M.L., Desjeux P., Loutan L., Koirala S. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. Roy. Soc. Trop. Med. Hyg. 2003, 97:350-354.
103. Rijal S., Ostyn B., Uranw S., Rai K., Bhattarai N.R., Dorlo T.P., Beijnen J.H., Vanaerschot M., Decuypere S., Dhakal S.S., Das M.L., Karki P., Singh R., Boelaert M., Dujardin J.C. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin. Infect. Dis. 2013, 56:1530-1538.
104. Ritt J.F., Raymond F., Leprohon P., Legare D., Corbeil J., Ouellette M. Gene amplification and point mutations in pyrimidine metabolic genes in 5-fluorouracil resistant Leishmania infantum. PLoS Negl. Trop. Dis. 2013, 7:e2564.
105. Rogers M.B., Hilley J.D., Dickens N.J., Wilkes J., Bates P.A., Depledge D.P., Harris D., Her Y., Herzyk P., Imamura H., Otto T.D., Sanders M., Seeger K., Dujardin J.C., Berriman M., Smith D.F., Hertz-Fowler C., Mottram J.C. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 2011, 21:2129-2142.
106. Salzberg S.L., Phillippy A.M., Zimin A., Puiu D., Magoc T., Koren S., Treangen T.J., Schatz M.C., Delcher A.L., Roberts M., Marcais G., Pop M., Yorke J.A. GAGE: A critical evaluation of genome assemblies and assembly algorithms. Genome Res. 2012, 22:557-567.
107. Sanchez-Canete M.P., Carvalho L., Perez-Victoria F.J., Gamarro F., Castanys S. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob. Agents Chemother. 2009, 53:1305-1313.
108. Selmecki A., Forche A., Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006, 313:367-370.
109. Selmecki A., Gerami-Nejad M., Paulson C., Forche A., Berman J. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 2008, 68:624-641.
110. Selmecki A., Forche A., Berman J. Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryot. Cell 2010, 9:991-1008.
111. Siegel T.N., Hekstra D.R., Kemp L.E., Figueiredo L.M., Lowell J.E., Fenyo D., Wang X., Dewell S., Cross G.A. Four histone variants mark the boundaries of polycistronic transcription units in Trypanosoma brucei. Genes Dev. 2009, 23:1063-1076.
112. Simpson J.T., Durbin R. Efficient de novo assembly of large genomes using compressed data structures. Genome Res. 2012, 22:549-556.
113. Simpson J.T., Wong K., Jackman S.D., Schein J.E., Jones S.J., Birol I. ABySS: a parallel assembler for short read sequence data. Genome Res. 2009, 19:1117-1123.
114. Singh N., Almeida R., Kothari H., Kumar P., Mandal G., Chatterjee M., Venkatachalam S., Govind M.K., Mandal S.K., Sundar S. Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology 2007, 134:777-787.
115. Singh R., Kumar D., Duncan R.C., Nakhasi H.L., Salotra P. Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites. Int. J. Antimicrob. Agents 2010, 36:50-57.
116. Sionov E., Lee H., Chang Y.C., Kwon-Chung K.J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010, 6:e1000848.
117. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 2001, 33:E57-61.
118. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 2004, 38:1266-1272.
119. Soto J., Rea J., Balderrama M., Toledo J., Soto P., Valda L., Berman J.D. Efficacy of miltefosine for bolivian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 2008, 78:210-211.
120. Sterkers Y., Lachaud L., Crobu L., Bastien P., Pages M. FISH analysis reveals aneuploidy and continual generation of chromosomal mosaicism in Leishmania major. Cell. Microbiol. 2011, 13:274-283.
121. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., Kumar P.C., Murray H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 2000, 31:1104-1107.
122. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., Berman J. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 2002, 347:1739-1746.
123. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 2007, 356:2571-2581.
124. Sundar S., Chakravarty J., Agarwal D., Rai M., Murray H.W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 2010, 362:504-512.
125. Thomas S., Green A., Sturm N.R., Campbell D.A., Myler P.J. Histone acetylations mark origins of polycistronic transcription in Leishmania major. BMC Genomics 2009, 10:152.
126. Torres E.M., Sokolsky T., Tucker C.M., Chan L.Y., Boselli M., Dunham M.J., Amon A. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007, 317:916-924.
127. Tripp C.A., Myler P.J., Stuart K. A DNA sequence (LD1) which occurs in several genomic organizations in Leishmania. Mol. Biochem. Parasitol. 1991, 47:151-156.
128. Ubeda J.M., Legare D., Raymond F., Ouameur A.A., Boisvert S., Rigault P., Corbeil J., Tremblay M.J., Olivier M., Papadopoulou B., Ouellette M. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 2008, 9:R115.
129. Ubeda J.M., Raymond F., Mukherjee A., Plourde M., Gingras H., Roy G., Lapointe A., Leprohon P., Papadopoulou B., Corbeil J., Ouellette M. Genome-wide stochastic adaptive DNA amplification at direct and inverted DNA repeats in the parasite Leishmania. PLoS Biol. 2014, 12:e1001868.
130. van Dijk E.L., Auger H., Jaszczyszyn Y., Thermes C. Ten years of next-generation sequencing technology 2014, Trends Genet.: TIG.
131. van Griensven J., Balasegaram M., Meheus F., Alvar J., Lynen L., Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis. 2010, 10:184-194.
132. van Luenen H.G., Farris C., Jan S., Genest P.A., Tripathi P., Velds A., Kerkhoven R.M., Nieuwland M., Haydock A., Ramasamy G., Vainio S., Heidebrecht T., Perrakis A., Pagie L., van Steensel B., Myler P.J., Borst P. Glucosylated hydroxymethyluracil, DNA base J, prevents transcriptional readthrough in Leishmania. Cell 2012, 150:909-921.
133. Vanaerschot M., Decuypere S., Downing T., Imamura H., Stark O., De Doncker S., Roy S., Ostyn B., Maes L., Khanal B., Boelaert M., Schonian G., Berriman M., Chappuis F., Dujardin J.C., Sundar S., Rijal S. Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J. Infect. Dis. 2012, 206:752-755.
134. Vasudevan G., Carter N.S., Drew M.E., Beverley S.M., Sanchez M.A., Seyfang A., Ullman B., Landfear S.M. Cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9873-9878.
135. Vasudevan G., Ullman B., Landfear S.M. Point mutations in a nucleoside transporter gene from Leishmania donovani confer drug resistance and alter substrate selectivity. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6092-6097.
136. Vega N.M., Allison K.R., Khalil A.S., Collins J.J. Signaling-mediated bacterial persister formation. Nat. Chem. Biol. 2012, 8:431-433.
137. White T.C., Fase-Fowler F., van Luenen H., Calafat J., Borst P. The H circles of Leishmania tarentolae are a unique amplifiable system of oligomeric DNAs associated with drug resistance. J. Biol. Chem. 1988, 263:16977-16983.
138. Yardley V., Croft S.L., De Doncker S., Dujardin J.C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 2005, 73:272-275.
139. Zerbino D.R., Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 2008, 18:821-829.